FountainVest China Capital Partners GP3 Ltd.

FountainVest China Capital Partners GP3 Ltd. is a fund-specific general partner entity associated with FountainVest Partners, a leading China-focused private equity group headquartered in Hong Kong. FountainVest was founded in 2007 by Frank Tang and partners as an independent, Greater China–oriented private equity manager investing long-term capital in growth and buyout opportunities across sectors tied to China’s structural transformation and domestic consumption. FountainVest China Capital Partners GP3 Ltd. appears in the U.S. regulatory framework as an institutional investment manager filing under CIK #0001795487. Its Form 13F submissions capture the reportable long U.S. equity and ADR positions held by the third-generation FountainVest China Capital Partners fund complex and related vehicles for which this GP entity has investment discretion. In practice, these positions are typically stakes in U.S.-listed Chinese or Greater China companies—often emerging from pre-IPO investments, PIPEs, or post-IPO holdings of portfolio companies—rather than a diversified public-equity strategy. The 13F data therefore represent only the listed, U.S.-traded slice of a predominantly private, Asia-centric portfolio that also includes Hong Kong and mainland China listings, private companies, and other instruments outside the 13F regime. When assembled into a coherent 13F History for this GP, the filings nonetheless offer a structured window into how one of FountainVest’s flagship fund generations has expressed its Chinese private equity positions in U.S. markets over time.

FountainVest’s overarching strategy—implemented at the fund level through entities such as FountainVest China Capital Partners GP3 Ltd.—is to make long-term, control or significant minority investments in leading Chinese and Greater China businesses that benefit from secular growth drivers. Core themes include rising domestic consumption, healthcare upgrade, financial services penetration, industrial upgrading and automation, logistics, and selected technology, media, and internet platforms. The investment process is fundamentally driven and partnership-oriented. The firm typically seeks: - Scalable business models with defensible market positions and strong brands or platforms - Robust cash-flow generation and disciplined capital allocation - Governance structures compatible with institutional ownership, including the ability to influence strategic direction - Entry valuations that provide a clear path to multiple and earnings expansion over a multi‑year horizon FountainVest creates value both through growth capital and buyout transactions—often working alongside management to professionalize operations, accelerate expansion, or execute strategic repositioning. Realization routes include domestic Chinese listings, Hong Kong IPOs, trade sales, and, importantly for 13F purposes, U.S. listings via ADRs on NYSE and Nasdaq. When portfolio companies list in the U.S., FountainVest may retain a meaningful stake for a period, which then appears in the 13F record for FountainVest China Capital Partners GP3 Ltd. As a result, the 13F-visible book for this GP is typically: - Highly concentrated in a limited number of U.S.-listed Chinese ADRs and related holdings - Long-only, with multi-year holding horizons tied to lock-up periods and exit strategies - Sector-tilted toward consumer, healthcare, TMT, and services businesses that fit the fund’s private equity thesis For allocators, analyzing the GP’s filings over time helps reconstruct the fund’s 13F Portfolio Composition—where in the U.S.-listed universe FountainVest has chosen to hold public exposure, how concentrated these positions have been, and how they evolve around IPOs, lock-up expiries, partial sell-downs, and final exits.

FountainVest China Capital Partners GP3 Ltd. represents the 13F-reporting face of a specific FountainVest fund generation, providing a look-through into how the GP has held and exited U.S.-listed stakes tied to its China private equity portfolio. The filings under CIK #0001795487 reveal a long-only, highly concentrated set of positions in Chinese and Greater China businesses that aligns with FountainVest’s sector focus on consumer, healthcare, TMT, and related services, and with its strategy of partnering with leading franchises through growth and buyout capital. When organized into a systematic 13F History and analyzed via a Portfolio Simulator, the data allow allocators to examine how the GP’s U.S.-listed exposures have evolved around IPOs and exit events, how concentration in key positions has changed over time, and how the liquid slice has behaved through major China-related market episodes. Performance Backtests Online built on this history help contextualize the capital trajectory and regime behavior of the U.S. sleeve, even as the bulk of the fund’s value sits in unlisted or non‑U.S. securities not reported on Form 13F. Because 13F-based analytics illuminate only part of the story—omitting private holdings, Hong Kong and onshore Chinese listings, and any financing or hedging overlays—they should be used as a complementary diagnostic alongside primary fund documentation, LP reports, and direct engagement with the manager. For allocators considering or monitoring exposure to FountainVest’s China-focused funds, a central question is how sensitive the listed component of FountainVest China Capital Partners GP3 Ltd.’s portfolio is to shifts in China’s regulatory stance, U.S.–China capital-market relations, and sector leadership within Chinese equities, and how that regime sensitivity interacts with the broader, less liquid private equity portfolio over time.

The economic risk faced by investors in FountainVest China Capital Partners funds is that of a concentrated, China-focused private equity portfolio: exposure to Chinese macro conditions, regulatory shifts, currency moves, sector cycles, and company-specific execution. The 13F data for FountainVest China Capital Partners GP3 Ltd. illustrate only the portion of that risk that materializes through U.S.-listed equities and ADRs. Within this listed sleeve, key risk characteristics include: - Single-name and sector concentration: Positions are often sizable stakes in a handful of consumer, healthcare, internet, or industrial names, so stock-specific and sector-specific outcomes can drive large swings in mark-to-market value. - China policy and regulatory risk: U.S.-listed Chinese companies have been sensitive to Beijing’s regulatory campaigns, changes in data and platform governance, and evolving rules around overseas listings, as well as to U.S.–China geopolitical tensions and ADR listing standards. - Liquidity and exit timing: Lock-up periods, trading volumes, and cross-border capital controls can affect the timing and price realization of exits, leading to lumpy capital flows when partial or full sell-downs occur. - Currency and de-listing dynamics: Movements in the renminbi and the risk of migration from U.S. listings to Hong Kong or onshore exchanges create additional complexity for U.S.-traded positions. If the 13F long book were viewed in isolation as a mark-to-market portfolio, it would likely exhibit a relatively high Volatility Profile and potentially deep interim drawdowns in periods of stress for Chinese equities, especially in regulatory or geopolitically driven selloffs. In practice, the private equity funds report valuations on a periodic basis, smoothing some of this day-to-day volatility and incorporating valuation methodologies for unlisted holdings that are not visible in 13F. Using the GP’s historical 13F holdings, allocators can replay the listed positions through time in a Portfolio Simulator or Backtesting Service—normalized to a user-defined notional—to construct a proxy Historical Track Record for the U.S.-listed sleeve. From that reconstructed capital path, one can estimate drawdown characteristics, sensitivity to China-related risk episodes, and an implied Sharpe Ratio for the visible positions. These metrics are best interpreted as a stress-testing tool for the liquid portion of the fund’s exposure, not as a full representation of private equity fund-level risk.